Navigation Links
ArtJen Announces Major Clinical Trial of Its Patented Weight Loss Product FBCx

WINDSOR, Ontario, Sept. 19 /PRNewswire/ -- ArtJen Complexus Holdings Corp. ( today announced that, following the results of their clinical trial with obese type 2 diabetics and an animal study at the National Institutes of Health, FBCx is being studied by a major US west-coast university medical center. The largest study to date on the patented all- natural soluble fiber that binds dietary fat will involve overweight but not obese individuals.

"Our earlier study with obese, type 2 diabetics demonstrated significant weight loss when adjusted for changes in diet." said FBCx co-inventor, Dr. Catherine Jen. "It's time to look at the non-obese population segment that would benefit from losing 10-25 pounds."

"We expect this study will show FBCx to be an easy and effective aid for losing weight and for lowering elevated levels of blood fats," continued FBCx co-inventor, Dr. Joseph Artiss.

Previous FBCx study findings include:

-- Effective at reducing and/or maintaining body weight in patients with

type 2 diabetes.

-- Lowered both triglyceride and LDL (bad) cholesterol levels in patients

who began the study with elevated triglyceride levels.

-- Blood work findings indicate an insulin sensitivity increase and

therefore a possible delay in the need to institute or the intensity of

insulin therapy in type 2 diabetics.

-- FBCx was shown to bind and remove 9 times its own weight in dietary

fat, essentially preventing 80 calories from being absorbed per tablet.

-- FBCx appears to preferentially bind saturated over unsaturated dietary


-- FBCx produced no adverse side effects.

These findings and others have lead to FBCx being referred to as the "miracle weight loss" pill in media reports and by renowned members of the medical profession.

"We are so convinced of the efficacy of FBCx that we sought out and funded this major study ourselves," said Dr. Artiss.

"I have spent my entire career studying obesity. FBCx works where most others have failed to live up to their hype," stated Dr. Jen.

FBCx co-inventors are Associate Professor of Pathology Joseph Artiss, Ph.D., FACB and K-L Catherine Jen, Ph.D., Professor and Chair of Nutrition and Food Science, both of Wayne State University in Detroit, Michigan.

Six tablets daily are capable of removing 50-60% of the calories from a typical North American diet.

SOURCE ArtJen Complexus Holdings Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:11/30/2015)... 2015 iCAD, Inc. (Nasdaq: ICAD ... latest solutions for advanced image analysis and workflow ... the Radiological Society of North American (RSNA) 2015 ... from November 29 to December 4, 2015. The ... an automated breast density assessment solution, PowerLook® Advanced ...
(Date:11/30/2015)... Texas , Nov. 30, 2015  Hanger, Inc. ... amendment and restatement of the terms of its previously ... Solicitation") relating to its $200,000,000 aggregate principal amount 7⅛% ... other things, (i) the consent fees payable pursuant to ... on the Notes and (iii) the expiration date of ...
(Date:11/30/2015)... Mexico Healthcare and Life Sciences Report 2015 . --> ... Pharmaboardroom releases its new 98-page Mexico Healthcare and Life Sciences ... country of over 122 million people. --> Latin ... --> It offers companies, investors, policymakers, and stakeholders with an ... largest pharma and healthcare market in Latin America ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... RoamRight, a leading provider of ... Public Television’s Travel With Kids to promote family vacations around the world. ... they explore international destinations and educate families about the people and places of the ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... disease-causing component of bacteria could be effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), ... University. , Their study showed that small molecule analogs that target the functions ...
(Date:11/30/2015)... ... 30, 2015 , ... At Grand Dental PC, their priority is to deliver ... have dental problems, you need to turn to a dentist who listens and responds; ... needs, a friendly dentist who counsels you on the best ways to maintain and ...
(Date:11/30/2015)... ... November 30, 2015 , ... Using a combination of ... in American children and adults, according to a new study by researchers at the ... Prediabetes in Children and Adults: Using Combinations of Blood Glucose Tests ,” published in ...
(Date:11/30/2015)... ... 2015 , ... Newly reviewed and approved “NJ Top Dentist”, ... He has both advanced training and considerable experience in reconstructive dentistry with attention ... cosmetic dentistry. He is an active Spear Education member providing full mouth ...
Breaking Medicine News(10 mins):